Skip to main content
. 2021 Nov 24;81(3):359–369. doi: 10.1136/annrheumdis-2021-220991

Figure 4.

Figure 4

Key secondary outcomes through week 48 of COSMOS. Primary analysis through week 24 and post hoc NRI analysis at week 48 of LSmean change and mean change in HAQ-DI score (A), ACR50 response (B), LSmean change and mean change in SF-36 PCS score (C), and PASI100 response (D). After week 24, analyses were performed using NRI (including imputation of EE patients as non-responders in the guselkumab group; see Patients and methods). Results for the placebo→guselkumab group at week 48 are reported for patients who did not enter EE and crossed over to guselkumab at week 24. ACR50, ≥50% improvement in American College of Rheumatology response criteria; GUS, guselkumab; HAQ-DI, Health Assessment Questionnaire-Disability Index; LS, least squares; NRI, non-responder imputation; PASI100, 100% improvement in Psoriasis Area and Severity Index; PBO, placebo; Q8W, every 8 weeks; SF-36 PCS, 36-item Short-Form Health Survey Physical Component Summary.